Quoin Pharmaceuticals Ltd. (QNRX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 6.61M USD | Liabilities, Current |
| Cash and equivalents | 3.85M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $6.61M | $3.85M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $5.35M | $3.12M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $5.55M | $3.82M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $5.76M | $1.83M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $4.34M | $1.67M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $4.86M | $3.82M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $4.18M | $3.62M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $3.47M | $3.12M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $3.95M | $2.85M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $4.22M | $1.83M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $3.58M | $2.40M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $4.58M | $3.16M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $4.41M | $4.76M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $4.16M | $3.37M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $3.53M | $2.86M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $3.60M | $5.25M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $3.67M | $2.69M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $7.48M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $323.83K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |